newsfilter
← Latest News
GlobeNewswire·

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

  • NEXGEL Inc. closed its acquisition of a commercial-stage regenerative biomaterials portfolio from Celularity Inc.
  • The transaction establishes BioNX Surgical, a new division focused on advanced biomaterials for tendon repair, soft tissue reconstruction, & bone regeneration.
  • NEXGEL acquired six established regenerative products with over a decade of clinical use & existing insurance reimbursement.
  • Three new product 510(k) filings are planned for 2026, 2027, & 2028.
  • The deal is expected to triple NEXGEL's annual revenue to approximately $35 million & be immediately accretive to profitability.
  • Financing includes a $5.5 million strategic investment from Sequence LifeScience™ via a convertible note with a $0.60 conversion price & 50% warrant coverage at a $0.80 strike price.
  • Sequence LifeScience™ will serve as a contract manufacturer for NEXGEL/BioNX & collaborate on developing new products leveraging NEXGEL's hydrogel technology.
  • The acquired products feature attractive gross margins & established reimbursement pathways to enable operating leverage.
  • NEXGEL hosted a shareholder update call on April 21, 2026, at 4:30 P.M. ET to discuss the transaction & partnership.